BackStrongbridge Biopharma plc Overview

Strongbridge Biopharma plc Total Current Liabilities

Strongbridge Biopharma plc's total current liabilities is $23M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$23.38M
20.02% YoYΔ $3.90M vs prior year quarter

Peer average

Loading

Strongbridge Biopharma plc Total Current Liabilities History

Loading

Strongbridge Biopharma plc vs. peers: Total Current Liabilities Comparison

Loading

Strongbridge Biopharma plc Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Strongbridge Biopharma plc (SBBP) FAQ

As of the most recent data (June 2021), SBBP shows a total current liabilities of $23M. That compares with $19M in the prior-year period — up 20.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBBP's total current liabilities is now $23M (was $19M) — a 20.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Strongbridge Biopharma plc is outperforming or lagging.

Tracking SBBP's total current liabilities over time shows whether Strongbridge Biopharma plc is scaling, shrinking, or reshaping that part of the business. The current reading is $23M That compares with $19M in the prior-year period — up 20.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Strongbridge Biopharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $23M) with ownership activity and broader fundamentals.

Strongbridge Biopharma plc's total current liabilities is $23M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.